抽象的

Judging response to cancer therapy RECIST and Beyond

Arvind K Chaturvedi

Monitoring response after treatment of cancer is an integral component of oncology practice. Objective tumor shrinkage has been widely regarded as a standard to judge response and is routinely used in everyday clinical practice to guide clinical decision-making. Imaging studies play a critical role in quantifying tumor response. The World Health Organization in 1979 laid down the WHO criteria for response assessment. The European organization for research and treatment of cancer came up with Response Evaluation Criteria in Solid Tumors in the year 2000 (RECIST). The RECIST documentation goes beyond lesion selection, measurement and assessment of response. It also makes specific recommendations on the usage of imaging techniques. RECIST was modified in 2009 to RECIST 1.1 which is the current standard for objective response assessment in most solid tumors. However, both WHO and RECIST criteria have relied upon size alone. It is well-known that cancer response to treatment is not always by reduction in size alone. RECIST doesn't work very well with Gastro Intestinal Stromal Tumors (GIST), mesotheliomas and Hepato Cellular Carcinoma (HCC) after locoregional therapies such as TACE and ablative treatments. For this reason, modified RECIST criteria (mRECIST) for HCC and Choi criteria for GIST have evolved. With many new anti-cancer drugs, particularly molecular targeted therapies, decrease in metabolic activity precedes any reduction in size. Also, very often as in lymphomas a non-viable residual mass without any viable tumor tissue may continue to be seen. As such PET-CT is being increasingly used today to monitor response. It is a part of the new PERCIST criteria and is the standard tool in assessing response in lymphomas. With increasing use of molecular targeted therapies and immunotherapy to treat many advanced cancers there is a fundamental change in the way cancers may respond. Cancer specific and therapy specific response criteria have become relevant in an era of personalized medicine. Paradoxically increase in size and even appearance of a new lesion may well be a part of the initial response inimmunotherapy. The evolution of response criteria, going beyond RECIST and evaluation of cancer and therapy specificresponse is the primary objective of this study.

Keywords: Lung Cancer, Cancer, Staging Cancer, Oncology, Tumor